TORONTO -- (MARKET WIRE) -- October 19, 2006 -- Generex Biotechnology Corporation (NASDAQ: GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, will make a podium presentation today at the 2006 Canadian Diabetes Association (CDA) Professional Conference and Annual Meetings in Toronto, Canada. The presentation, to be made by Dr. Gerald Bernstein, the Company's Vice-President for Medical Affairs, relates to Generex Oral-lyn™, the Company's proprietary oral insulin spray product, and is of a paper entitled 3-Month Interim Results (6-Month Study) on Safety and Efficacy of an Oral Insulin (Generex Oral-lyn™) Administered at Lunchtime in Juvenile Type-1 Diabetes Mellitus Subjects Maintained on Basal Glargine Insulin and Pre-Breakfast and Pre-Dinner Regular Insulin. The paper was co-authored by Drs. Jaime Guevara-Aguirre, Marco Guevara-Aguirre and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR in Quito, Ecuador.
